TABLE 2.
Study Period Treatment Patterns
| Treatment Pattern Outcomesa | Telaprevir Patients (n = 871) | Boceprevir Patients (n = 284) |
|---|---|---|
| Therapy segment initiation, n (%) | ||
| Lead-in therapy (PEG + RBV) | — | 185 (65.1) |
| Triple therapy (index drug + PEG + RBV) | 845 (97.0) | 278 (97.9) |
| Dual therapy (PEG + RBV) | 651 (74.7) | 121 (42.6) |
| Therapy duration (weeks),b mean ± SD | ||
| Index drug | 11.9 ± 4.4 | 24.9 ± 13.3 |
| Overall (lead-in+triple+dual) | 25.6 ± 14.9 | 28.6 ± 13.6 |
| Lead-in therapy | — | 3.3 ± 0.9 |
| Triple therapy | 11.6 ± 4.2 | 23.9 ± 12.8 |
| Dual therapy | 18.2 ± 12.0 | 5.8 ± 6.0 |
| Therapy noncompletion,c n (%) | 470 (54.0) | 210 (73.9) |
a Guidelines differ for each DAA; as such, certain outcomes of interest vary by treatment.
b All therapy duration outcomes are calculated only among those patients with nonzero duration for that segment.
c Noncompletion of the DAA-based regimen was defined as not completing at least 12 weeks of triple therapy followed by at least 12 weeks of dual therapy for telaprevir and not completing at least 3 weeks of lead-in treatment followed by at least 24 weeks of triple therapy for boceprevir.
DAA = direct-acting antiviral; PEG = peginterferon alfa; RBV = ribavirin; SD = standard deviation.